Antihypertensive Medications: Types, Uses, & Side Effects

Antihypertensive medications lower blood pressure through several distinct mechanisms, and doctors currently choose from more than a half-dozen drug classes depending on a patient’s age, kidney function, ethnicity, pregnancy status, and other health conditions. The most widely prescribed first-line options are thiazide diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers, with beta-blockers, mineralocorticoid receptor antagonists, and direct vasodilators filling important roles in specific situations. Because each class works differently, the side-effect profiles vary considerably, and understanding those differences helps explain why your doctor may switch you from one drug to another or combine several at low doses.

Thiazide Diuretics

Thiazide and thiazide-like diuretics (hydrochlorothiazide, chlorthalidone, indapamide) are among the oldest and cheapest blood-pressure drugs still in routine use. They work in the kidneys by blocking sodium reabsorption, which pulls extra fluid out of the bloodstream. That initial fluid loss isn’t the whole story, though. Over time, researchers believe the blood-pressure benefit also comes from direct relaxation of blood vessel walls and a compensatory adjustment to the early drop in how much blood the heart pumps per beat.

The trade-off is a set of metabolic side effects. Thiazides can push blood sugar higher and are linked to low potassium, elevated uric acid, and changes in fat metabolism. The connection between thiazide-induced low potassium and worsening blood sugar control has been recognized for decades, though the exact chain of events remains debated; theories include effects on insulin release from the pancreas and increased belly fat.¹ For most people these shifts are minor and manageable with periodic blood tests, but if you already have gout or poorly controlled diabetes, your doctor may lean toward a different class.

ACE Inhibitors

ACE inhibitors (lisinopril, enalapril, ramipril, and others ending in “-pril”) block an enzyme that converts a hormone called angiotensin I into angiotensin II, a powerful vessel-constricting chemical. With less angiotensin II circulating, blood vessels relax and blood pressure falls. ACE inhibitors also reduce the breakdown of bradykinin, a substance that widens blood vessels. That’s the good part. The annoying part is that the same bradykinin buildup irritates nerve fibers in the airways, which is why a persistent dry cough is the most common reason people stop taking these drugs.²

A more serious but far rarer side effect is angioedema, a sudden swelling of the face, lips, tongue, or throat that can obstruct breathing. This affects roughly one to two out of every thousand patients on ACE inhibitors and usually shows up within the first week.² ACE inhibitors are also contraindicated in pregnancy because they can cause serious harm to a developing fetus, particularly kidney damage.

Angiotensin Receptor Blockers

ARBs (losartan, valsartan, candesartan, and others ending in “-sartan”) target the same hormonal pathway as ACE inhibitors but at a different point: instead of preventing angiotensin II from being made, they block the receptor it binds to. The practical advantage is that ARBs don’t cause bradykinin to accumulate, so the dry cough problem largely disappears. In a meta-analysis of patients who had been intolerant of ACE inhibitors, ARBs produced far fewer cough events and had a cough rate similar to placebo.³ A study of losartan cough reports found that the vast majority of patients who stopped losartan because of cough had previously been on an ACE inhibitor and had experienced cough with that drug, suggesting carry-over attribution rather than a true losartan effect.⁴

ARBs are not free of side effects, however. Compared with placebo, they carry higher rates of low blood pressure, kidney function changes, and elevated potassium.³ A large network meta-analysis found that ARB-containing regimens actually had fewer treatment discontinuations due to adverse effects than placebo, making them among the best-tolerated antihypertensive options available.⁵

Calcium Channel Blockers

Calcium channel blockers (amlodipine, nifedipine, diltiazem, verapamil) prevent calcium from entering smooth-muscle cells in artery walls, causing those muscles to relax and blood vessels to widen. The two main subgroups behave differently: dihydropyridines like amlodipine mainly target the arteries, while non-dihydropyridines like diltiazem and verapamil also slow the heart rate, which makes them useful for certain heart-rhythm problems but potentially troublesome if your heart rate is already low.

The signature side effect of the dihydropyridine group is ankle swelling, caused by fluid leaking into tissue when small arteries dilate more than small veins. Flushing, headache, and a racing heartbeat can also occur, especially at higher doses. Constipation is more characteristic of verapamil specifically. In the network meta-analysis mentioned above, calcium channel blockers as a class showed higher treatment discontinuation rates than placebo, largely because of these side effects.⁵

Beta-Blockers

Beta-blockers (atenolol, metoprolol, bisoprolol, carvedilol, nebivolol) lower blood pressure by slowing the heart and reducing the force of each beat. They also suppress the release of renin, a kidney enzyme that kicks off the hormonal cascade leading to higher pressure. For decades they were considered a first-line option, but current guidelines have pulled them back from that role in straightforward hypertension. They are not recommended as initial therapy without a compelling indication like heart failure or a recent heart attack, especially in older adults.⁶

A key concern is their metabolic footprint. Older beta-blockers worsen insulin resistance and raise triglycerides in a dose-dependent way, which matters a lot for patients already at risk of diabetes.⁶ Newer vasodilating beta-blockers like carvedilol and nebivolol appear to have a friendlier metabolic profile and don’t seem to tip the scales toward glucose or lipid problems in the same way. Whether that metabolic advantage translates into fewer heart attacks and strokes over the long run has not yet been proven in a large outcomes trial.⁷ Common nuisance side effects include fatigue, cold hands, and sexual dysfunction.

Drugs for Resistant Hypertension

When blood pressure stays above target despite three different drugs at adequate doses (one of which should be a diuretic), doctors diagnose resistant hypertension. This is where less commonly used agents step in. Spironolactone, a mineralocorticoid receptor antagonist, has shown impressive results in this population. Across multiple prospective studies, adding spironolactone to existing regimens lowered blood pressure by an average of about 22/10 mmHg.⁸ The main side effects to watch for are elevated potassium, worsening kidney function, and anti-androgen effects: breast tenderness and breast enlargement in men (gynecomastia), and menstrual irregularities in women.⁹

A newer alternative, eplerenone, is more selective for the aldosterone receptor and much less likely to cause those hormonal side effects. However, it is also less potent at lowering blood pressure, and spironolactone remains the preferred add-on drug for resistant hypertension based on the strongest available trial data. Eplerenone is typically reserved for patients who can’t tolerate spironolactone’s anti-androgenic effects.¹⁰

Direct vasodilators like hydralazine and minoxidil relax blood vessel walls from the inside. They’re effective, but using them alone triggers a reflexive speed-up of the heart and fluid retention as the body tries to compensate, so they are almost always combined with a beta-blocker and a diuretic.¹¹ Clonidine, a centrally acting drug that dials down sympathetic nervous system output, is another option in refractory cases, though drowsiness and rebound high blood pressure if a dose is missed limit its appeal.

Why Most People End Up on More Than One Drug

A single antihypertensive drug at a standard dose controls blood pressure in only a fraction of patients. That’s not a failure of any individual drug; it reflects the reality that high blood pressure has multiple contributors, and blocking just one pathway often isn’t enough. Current guidelines increasingly favor starting two drugs at lower doses rather than pushing one drug to its maximum, because side effects tend to be dose-dependent while the blood-pressure benefit of combining two mechanisms is roughly additive.

Convenience matters here. When two or three drugs are bundled into a single pill, patients are substantially more likely to keep taking them. A systematic review and meta-analysis found that adherence and persistence were significantly better with single-pill combinations compared with taking the same drugs as separate tablets, and blood pressure was slightly but meaningfully lower at twelve weeks.¹² An American Heart Association scientific statement has endorsed single-pill combinations for their ability to simplify regimens, overcome prescriber inertia, and achieve faster blood pressure control.¹³ Common pairings include an ACE inhibitor or ARB with a calcium channel blocker, or an ACE inhibitor or ARB with a thiazide diuretic.

Blood Pressure Drugs During Pregnancy

Pregnancy sharply narrows the menu. ACE inhibitors and ARBs are off-limits because of the risk of fetal kidney damage and other birth defects. The drugs with the longest safety track record in pregnancy are labetalol (a combined alpha- and beta-blocker), nifedipine (a calcium channel blocker), and methyldopa (a centrally acting agent).¹⁴ Older studies raised concerns about birth defects with some of these drugs, but more recent evidence suggests those findings likely reflected the higher baseline rate of congenital abnormalities in women with chronic high blood pressure, not the drugs themselves.¹⁴

A network meta-analysis of antihypertensives in pregnancy found that all commonly prescribed drugs reduced the risk of severe hypertension, but labetalol may carry additional advantages in lowering the risk of preeclampsia and fetal or newborn death.¹⁵ Evidence for many safety outcomes remains thin, so this is an area where prescribing is still guided heavily by clinical experience.

Kidney Disease and Diabetes

ACE inhibitors and ARBs occupy a special place in the treatment of patients who have both high blood pressure and kidney disease or diabetes. By blocking the renin-angiotensin system, they reduce pressure inside the kidney’s filtering units, which slows the progressive loss of kidney function and reduces protein leakage into the urine. A systematic review of randomized trials confirmed that this approach remains a cornerstone of chronic kidney disease management, though it requires careful monitoring of potassium and kidney function, especially in patients already at risk of elevated potassium.¹⁶ Combining an ACE inhibitor with an ARB (“dual blockade”) is generally avoided because it raises the risk of dangerous side effects without clear added benefit.

Does It Matter When You Take Your Pill?

The idea that taking blood pressure medication at bedtime instead of in the morning could prevent more heart attacks and strokes generated a lot of excitement a few years ago. More recent and rigorous evidence has tempered that enthusiasm. The TIME study, a large pragmatic trial of over 21,000 participants, found no difference in vascular death, heart attack, or stroke between morning and evening dosing. The study’s conclusion was straightforward: patients should take their medication at whatever time is most convenient, because timing makes no difference to cardiovascular outcomes.¹⁷

A separate trial focused specifically on frail older adults reached the same conclusion: switching antihypertensives to bedtime did not reduce death or major cardiovascular events.¹⁸ That said, a smaller study did find that bedtime dosing produced a modestly larger drop in nighttime blood pressure (about 3 mmHg systolic more than morning dosing), with better nighttime blood pressure control and no increase in overnight low-pressure episodes.¹⁹ For most people, the practical takeaway is to pick a time you’ll remember and stick with it. If your doctor specifically wants your nighttime readings lower, evening dosing may be worth discussing, but the overall evidence for hard outcomes like heart attacks doesn’t support a blanket recommendation.

Side Effects and Why People Stop Treatment

Uncontrolled high blood pressure has no symptoms in most people, which means any side effect from treatment feels like it’s making a well person feel worse. That asymmetry drives a lot of the adherence problems. A study that looked at why patients skip doses found that tiredness, muscle pain, and poor sleep were the strongest predictors of non-adherence, with patients who attributed symptoms to their medication being over three times as likely to have poor adherence. Those who actually changed their pill-taking behavior because of symptoms were over sixteen times as likely to be classified as non-adherent.²⁰

Not all drug classes contribute equally to this problem. The network meta-analysis across drug classes found that calcium channel blockers, ACE inhibitor–CCB combinations, and beta-blocker–thiazide combinations all significantly increased treatment discontinuation compared with placebo. ARBs, by contrast, actually had fewer discontinuations than placebo, and ARB-plus-CCB combinations were also well tolerated.⁵ If you’re struggling with side effects, tell your doctor rather than quietly stopping. There is almost always a combination that works without making you miserable.

Genetic Variation in Drug Response

You may have heard that certain blood pressure drugs work better in people of different ethnic backgrounds. There is truth to this: clinical trial data consistently show that Black patients tend to have a smaller blood-pressure response to ACE inhibitors, ARBs, and beta-blockers compared with white patients, while responses to thiazide diuretics and calcium channel blockers are more similar across groups. But the underlying reason isn’t really about race as a biological category. A study that looked at genetic ancestry rather than self-reported ethnicity found that differences in drug response were more closely linked to genetically defined ancestry than to how patients identified themselves. A relatively small number of gene variants with differing frequencies across populations explained a large proportion of the response gap.²¹

Research into pharmacogenomics has confirmed that geographic origin strongly influences the distribution of gene variants relevant to blood pressure drug metabolism, with dozens of pharmacogenes showing geographic differentiation.²² In clinical practice, race-based prescribing guidelines serve as a rough proxy for these genetic differences, but the field is moving toward a genomic precision approach that could individualize drug selection without relying on ethnicity as a stand-in.

Over-the-Counter Drugs That Can Raise Your Blood Pressure

One of the most overlooked reasons a blood pressure regimen stops working is something the patient started taking on their own. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are the most important offenders. They interfere with prostaglandins in the kidney, causing sodium and water retention and blunting the effect of many antihypertensives. This isn’t a rare or subtle interaction; it can add several points of systolic pressure and undermine what was previously well-controlled treatment. Decongestants containing pseudoephedrine or phenylephrine are another common culprit. If you’re on blood pressure medication and reach for a cold remedy, check the label or ask a pharmacist. Some antidepressants can also push blood pressure up in a meaningful fraction of patients.

Emerging Drug Classes

For patients with resistant hypertension who still aren’t controlled despite spironolactone and other add-on agents, the pipeline holds some promise. Aldosterone synthase inhibitors are a new class that reduce aldosterone production by targeting the enzyme responsible for making it, rather than blocking the receptor after it’s already been released. Baxdrostat, the furthest along in development, selectively inhibits the CYP11B2 enzyme without significantly affecting cortisol production, a key advantage over older adrenal-targeting drugs.²³ In a Phase 2 trial, baxdrostat significantly lowered both systolic and diastolic blood pressure in patients with resistant hypertension, with the 2 mg dose showing the most consistent benefit.²³ Phase 3 trials are underway.²⁴

The Cost Question

Most of the first-line antihypertensive classes have been generic for years, and a month’s supply of drugs like lisinopril, amlodipine, or hydrochlorothiazide can cost just a few dollars. Newer branded drugs, single-pill combinations, and medications like eplerenone carry higher price tags. A cross-sectional study looking at affordability of antihypertensives found that generic drugs were consistently more affordable than their brand-name originals, and that centralized procurement policies dramatically improved affordability for both.²⁵ Where insurance coverage is limited, generic substitution can be the difference between a patient taking their medication and not.

Treatment thresholds themselves have shifted over time. Professional societies have repeatedly lowered the blood pressure numbers at which they recommend starting drug therapy, meaning more people are considered candidates for medication than in previous decades.²⁶ That trend makes affordability and tolerability even more important, because the population being treated is larger and includes many people with only modestly elevated readings who are less likely to tolerate side effects that feel worse than their condition.